You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 四環醫藥(0460.HK)大漲超20% 擬收購創新驅動型生物公司康明百奧
格隆匯 01-26 13:10
格隆匯1月26日丨四環醫藥(0460.HK)午後漲幅擴大,現報1.76港元,大漲20.55%,暫成交4億港元,最新總市值166億港元。四環醫藥今日午間宣佈,公司已簽訂框架協議以收購北京康明百奧。康明百奧是一家致力於創新雙抗、雙抗ADC等多功能抗體藥物研發的創新驅動型生物公司,為國家高新技術企業及中關村高新技術企業。收購完成後,公司將會成為康明百奧的擁有人。公吿還稱,康明百奧的業務聚焦於大分子藥物的開發,擁有海內外的自主研發團隊,擁有實力強大的自主研發技術平台。集團相信該收購將是集團佈局大分子板塊的里程碑事件。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account